Zydus Cadila gets USFDA nod for Pyridostigmine Bromide tablets

Rutam Vora Ahmedabad | Updated on January 24, 2018 Published on June 24, 2015

City-based healthcare major Zydus Cadila on Wednesday informed that the company has received final approval from the US drug regulator, USFDA, to market Pyridostigmine Bromide Tablets USP, 60 mg.

Pyridostigmine Bromide tablets are used in the treatment of various neurological disorders.

According to a company statement, the estimated sales for Pyridostigmine Bromide Tablets USP in 2015 is $27.9 million.

The group now has 100 approvals and has so far filed over 260 ANDAs since the commencement of the filing process in FY 2003-04.

Cadila Healthcare shares were trading at Rs 1,774, up over 2 per cent from the previous close on the BSE.


Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

Published on June 24, 2015
This article is closed for comments.
Please Email the Editor